Evaluation of Intestinal Permeability in Cirrhotic Patients Before and After Treatment With Non-selective Beta Blocker (Propranolol)

• Status: Unknown status
• Trial end date: 2020-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This study seeks to investigate whether non-selective beta blocker treatment decreases intestinal permeability in cirrhotic patients by altering the expression of genes encoding intercellular junction proteins.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
• Treatments: Adrenergic beta-Antagonists; Propranolol

Criteria

Inclusion Criteria:

• > 18 years

• Diagnosis of cirrhosis of any etiology or severity as established by the treating physician (biopsy, biochemical, imaging)

• High risk gastroesophageal varices, that is those with medium/large varices or any size varices with red wale signs

• Scheduled appointment for endoscopic ligation as previously ordered by the treating physician

• Signed informed consent

• Ability to keep return appointments

Exclusion Criteria:

• Beta blocker treatment within 1 month prior to study period

• Antibiotic treatment during or within 1 month prior to study period

• Prebiotic or probiotic treatment during or within 1 month before study period

• Current immunosuppressive treatment

• Patients with active infectious process

• Patients with portal thrombosis

• Patients with hepatocellular carcinoma

• Patients with intestinal surgical shunts

• Patients with chronic diarrhea or documented celiac disease

• Patients with chronic renal failure (KDOQI: ≤ 3)

• Patients with allergy or absolute contraindication for the use of nonselective beta blockers (asthma, significant heart block, systolic BP <90 mm Hg, basal HR <55, refractory ascites)